Symeres Acquires Oncolines
January 10, 2023
Symeres, the Netherlands-headquartered transatlantic CRO & CDMO backed by Keensight Capital, has acquired Oncolines, an Oss-based oncology-focused CRO that provides early biology services and cell-line profiling assays. The add-on expands Symeres' oncology and precision-medicine biology capabilities and brings Oncolines' ~20 employees into the Symeres platform (part of NTRC Holding), increasing the group's integrated drug-discovery offering and proforma revenues to over €100m.
- Buyers
- Symeres, Keensight Capital
- Targets
- Oncolines
- Sellers
- NTRC Holding
- Platforms
- Symeres
- Industry
- Healthcare Services
- Location
- North Brabant, Netherlands
- Transaction Type
- Addon
Explore More
Related Acquisitions
-
Symeres Acquires DGr Pharma
September 15, 2025
Healthcare Services
Symeres has acquired DGr Pharma to strengthen its early‑stage drug development and regulatory consultancy capabilities, accelerating IND‑enabling services for biopharma clients. The deal is supported by Keensight Capital, which backs Symeres and aims to expand the platform's integrated CRDMO offering across discovery and early clinical development.
-
Symeres Acquires Exemplify BioPharma
October 25, 2022
Pharmaceuticals
Symeres, a Netherlands-headquartered transatlantic CRO/CDMO majority‑owned by Keensight Capital, has acquired Exemplify BioPharma, a Cranbury, New Jersey-based CMC-focused CRO. The deal strengthens Symeres' capabilities in process and analytical chemistry and formulation development and further expands its strategic foothold in the United States.
-
Syros Pharmaceuticals Acquires Tyme Technologies in $130M PIPE and Closes Merger
September 16, 2022
Biotechnology
Syros Pharmaceuticals (NASDAQ: SYRS) closed its merger with Tyme Technologies, acquiring TYME’s pipeline assets and net cash at closing. The transaction included a concurrent oversubscribed $130 million private investment in public equity (PIPE), and the combined company trades on Nasdaq under the SYRS ticker.
-
Symeres Acquires Organix Inc.
April 26, 2022
Biotechnology
Symeres, a European drug discovery CRO/CDMO backed by Keensight Capital, has acquired Organix Inc., a Woburn, Massachusetts-based organic chemistry services provider specializing in lipids. The deal gives Symeres a strategic US foothold and expands its capabilities into the fast-growing lipids market supporting mRNA therapeutics and vaccines; Organix generates over $10 million in revenue and has roughly 45 employees.
-
Keensight Capital Acquires Majority Stake in Symeres from Gilde Healthcare
May 25, 2021
Healthcare Services
Keensight Capital will acquire a majority stake in Symeres, a leading European small-molecule CRO and CDMO, from Gilde Healthcare with management co-investing. The investment will fund organic growth and further M&A to expand Symeres' drug discovery, development and manufacturing capabilities across Europe and globally.
-
Chimerix Acquires Oncoceutics
January 7, 2021
Biotechnology
Chimerix (NASDAQ: CMRX) acquired clinical-stage Oncoceutics, gaining the late-stage oncology candidate ONC201 to expand its oncology pipeline. The deal closed January 7, 2021, for $78 million (half stock, half cash) plus potential milestones and royalties.
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.